KLRK1 and melanoma: Furthermore, altered NKG2D ligand expression during BRAFi therapy could also be a consequence of IFN‐γ release by activated T and NK cells.51, 52 Unchanged MHC‐class I levels in BRAFi‐treated tumors should make the cells susceptible to T‐cell mediated recognition and killing; however, expression of melanoma antigens is lowered upon prolonged BRAFi therapy as seen in our study and other mouse as well as human studies.18, 20, 53